journal article
LitStream Collection
doi: 10.1038/nbt0306-227pmid: 16525363
The best-performing stock from 2005 was a prime example of how biotech stocks are not as capricious as they may seem.
doi: 10.1038/nbt0306-229pmid: 16525364
Diversa recently announced plans to restructure, and although officials insist that the company is not eliminating its research operations, it is certainly turning away from a rich heritage of scientific exploration.
doi: 10.1038/nbt0306-230pmid: 16525365
An emerging class of highly specific immunomodulator drugs targeting toll-like receptors will be the focus of attention this month at a conference in Salvador, Brazil.
Orellana, Claudia; Neto, Ricardo Bonalume
doi: 10.1038/nbt0306-232pmid: 16525366
Rising oil prices and apprehension about global warming are prompting governments to rethink their energy supply policies.
doi: 10.1038/nbt0306-235pmid: 16525368
With a knack for attracting the right scientists, Bob Tjian set out to build a mega-biotech conglomerate. He fell short of his lofty goal, but his company was still a success.
Wilan, Ken Howard; DeFrancesco, Laura
doi: 10.1038/nbt0306-237pmid: 16525369
Biotech companies will be facing particular ethical challenges as their products enter the marketplace. How is the industry preparing? Ken Wilan investigates.
doi: 10.1038/nbt0306-240pmid: 16525370
It was US investors that largely bankrolled the biotech industry over the past 25 years. Is all that about to change? Michael Fitzgerald investigates.
doi: 10.1038/nbt0306-249pmid: 16525371
What changes, if any, can we expect in the system currently used to protect biotech inventions?
Showing 1 to 10 of 55 Articles